Accelerating CNS Drug Discovery: An Integrated in silico and in vitro Approach that Rapidly Contributes to Compound Design Leading to Increased Success in vivo

Design Smarter CNS Drugs, Faster

Discover how Sygnature Discovery combines in silico predictions and in vitro data to guide compound selection for central nervous system (CNS) drug discovery, before going in vivo.

This integrated approach enables better predictions of BBB penetration, MDR1 efflux avoidance, and human dose estimation, leading to more informed compound design and reduced animal use.

Download the free poster to see how this workflow helps accelerate CNS projects from idea to in vivo confirmation.